Pfizer to offer small Covid vax packaging to cut wastage of doses

US drug maker Pfizer aims to roll out smaller packages of its Covid-19 vaccine for public health departments and care providers by October, media reports said.

Pfizer Vaccine, Coronavirus vaccine
Photo: Shutterstock
IANS Washington
2 min read Last Updated : Sep 06 2021 | 8:11 PM IST

US drug maker Pfizer aims to roll out smaller packages of its Covid-19 vaccine for public health departments and care providers by October, media reports said.

Pfizer is working on smaller packing options, the drug maker said in a statement to CBS News.

The change can help increase the availability of vaccines in smaller, more rural areas and decrease the number of wasted doses.

Currently, Pfizer's mRNA Covid vaccine is available in two packages: one with 450 doses and another with 1,170. But the vaccine's cold storage requirement limits where and for how long they can be kept, making it challenging for smaller facilities to store high quantities of the vaccine without wasting doses.

The US Centers for Disease Control and Prevention, last month, updated the immunisation partners of the potential change -- revealed a document obtained by CBS News.

While the CDC document did not specify what the new packaging would entail, it told partners to "stay tuned for more details".

The change could allow shipments to go directly to doctor's offices, Dr Marcus Plescia, chief medical officer for the Association of State and Territorial Officers, was quoted as saying.

Presently, doses meant for locations without sufficient storage capabilities are often siphoned off from a larger facility where they're held to reduce waste, the report said.

More than 14.5 million doses have been wasted so far, roughly 3.4 per cent of all delivered doses, a CDC spokesperson said last week.

Jabs delivered in multidose vials, like the Covid-19 shots, typically have a waste rate of 5-15 per cent, the spokesperson added.

Meanwhile, Pfizer's booster shot is likely to get US Food and Drug Administration and CDC approval for a rollout by September 20. Moderna may get delayed.

As of now, an additional dose of either Pfizer or Moderna has been authorised for Americans who are immunocompromised. More than 1.3 million such immunocompromised individuals have received an additional shot, according to the CDC.

--IANS

rvt/vd

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusPfizerCoronavirus Vaccine

First Published: Sep 06 2021 | 8:11 PM IST

Next Story